OTC:LIANY
LianBio
LianBio (LIANY) is a cash-rich biopharma developer of AVE12835, targeting severe liver diseases with a strong balance sheet but no current product sales.
Key Metrics
Investment Thesis
Bull Case
LianBio offers an attractive speculative opportunity for investors willing to back high-potential late-stage biotech assets with a clean balance sheet and minimal debt. The substantial cash hoard of $223 million in marketable securities provides a long runway, potentially allowing the company to emerge from clinical trials with significant value if AVE12835 achieves approval.
Bear Case
The stock carries extreme risk due to zero revenue and a massive net loss that has eroded equity significantly, leaving shareholders with a substantial deficit. Without proven commercialization milestones or successful trial data, the company faces an existential threat of cash depletion before generating any income to service its obligations.
About LianBio
LianBio is a biopharmaceutical company focused on developing innovative medicines for severe liver diseases, leveraging its proprietary AVE12835 drug candidate targeting hepatobiliary pathologies. The firm serves the global market for rare liver conditions and leverages significant cash reserves to fund high-risk R&D programs without current commercial revenue streams.
Analysis
Management Discussion
Management has deployed substantial capital expenditures and invested heavily in R&D spending of nearly $60 million to advance its pipeline, resulting in a net loss of over $110 million. Despite the negative operating cash flow, the company successfully maintained its cash position around $79 million by managing liabilities effectively, though it continues to accumulate a significant retained earnings deficit.
Industry Overview
The hepatobiliary therapeutics sector is characterized by high barriers to entry and significant investment requirements for drug development in rare disease spaces. Companies in this niche often lack revenue until late-stage clinical trials succeed, creating a binary investment profile dependent on regulatory approval pathways and partnership deals.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Operating Expenses | $125.4M |
| Operating Income | $-125.4M |
| R&D | $59.8M |
| G&A | $65.6M |
| Stock-Based Comp | $19.1M |
| Depreciation | $1.0M |
| Other OpEx | $0 |
| Non-Operating Income | $14.7M |
| Pre-Tax Income | $-110.6M |
| Income Tax | $-333.0K |
| Continuing Ops | $-110.3M |
| Discontinued Ops | $0 |
| Net Income | $-110.3M |
| Minority Interest | $0 |
| Net to Common | $-110.3M |
| Metric | 2022 |
|---|---|
| Current Assets | $312.8M |
| Cash & Equivalents | $79.2M |
| Marketable Securities | $223.1M |
| Prepaid Expenses | $8.6M |
| Other Current Assets | $1.8M |
| Long-Term Assets | $7.2M |
| PP&E (Net) | $3.1M |
| Operating Leases | $4.0M |
| Other LT Assets | $93.0K |
| Total Assets | $320.0M |
| Current Liabilities | $23.6M |
| Accounts Payable | $1.5M |
| Current Leases | $1.9M |
| Other Current Liab | $485.0K |
| Long-Term Liabilities | $2.7M |
| LT Operating Leases | $2.5M |
| Other LT Liab | $210.0K |
| Total Liabilities | $26.3M |
| Shareholders' Equity | $293.6M |
| Retained Earnings | $-470.5M |
| AOCI | $-2.1M |
| Total L&E | $320.0M |
| Metric | 2022 |
|---|---|
| Net Income (CFO) | $-110.3M |
| Non-Cash Adjustments | $3.0M |
| Working Capital Changes | $8.1M |
| Cash from Operations | $-99.2M |
| Capital Expenditures | $1.8M |
| Cash from Investing | $-69.2M |
| Cash from Financing | $1.7M |
| FX Effect | $-2.2M |
| Net Change in Cash | $-168.9M |
| Beginning Cash | $248.2M |
| Ending Cash | $79.3M |
Frequently Asked Questions
How does LianBio make money?
The company operates primarily through its pharmaceutical development segment, focusing on the clinical advancement and eventual commercialization of AVE12835 for hepatobiliary indications. Due to the absence of revenue in the financial data, there are no separate commercial or licensing revenue streams active at this stage.
What are the main risks for LIANY?
The primary risk is the complete lack of revenue generation, relying entirely on burning through cash reserves which totaled nearly $100 million in negative operating cash flow last year. Investors face high clinical trial failure risks typical of early-stage biotech, and potential regulatory hurdles in bringing novel mechanisms to market for rare diseases.
What is LIANY's competitive advantage?
LianBio holds a significant first-mover advantage with its lead candidate AVE12835 in the treatment of severe liver diseases like primary biliary cholangitis. The company possesses a robust balance sheet with over $79 million in cash and equivalents, providing ample runway to navigate clinical trials without immediate need for dilutive financing.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.